ReviewFrontiers in oncology2023

The toxicity associated with combining immune check point inhibitors with tyrosine kinase inhibitors in patients with non-small cell lung cancer.

Anjali Kalra et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.